TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 250nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 250nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 260nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 290nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 340nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 380nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 390nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 480nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 520nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 520nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 600nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 650nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 650nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 710nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 770nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 850nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 850nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 970nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.12E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.29E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.41E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.68E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 2.25E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 2.25E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 2.28E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 2.64E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 3.00E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 3.00E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 3.12E+3nMAssay Description:Inhibition of SFLLRN-NH2-stimulated PAR1-mediated platelet activation in platelet-rich human plasma assessed as surface expression of P-selectin afte...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 4.00E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 4.00E+3nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 6.00E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 7.00E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 8.00E+3nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20E+4nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70E+4nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
Affinity DataIC50: 1.95E+4nMAssay Description:Assay details: A SARS-Cov-2 Mpro construct was prepared, which includes a His-tag and PreScission cleavage site (see FIG. 3A). The construct was tran...More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 2.25E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: 2.25E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair
TargetProtein disulfide-isomerase(Homo sapiens (Human))
Beth Israel Deaconess Medical Center
US Patent
Beth Israel Deaconess Medical Center
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:Insulin reductase assay.More data for this Ligand-Target Pair